Is there a demand for consumer stocks?
While some consumer stocks are performing well, some investors are becoming more cautious about paying a premium in a cooling market


Branded consumer staples are usually seen as a very defensive sector. They tend to beat the market when investors get nervous about growth. That pattern isn’t playing out as reliably as it normally does in this cycle.
While a few staples firms are performing very well – Colgate Palmolive is up 25% this year – many other stalwarts, from Nestlé to Mondelez, are not. In some cases, the weakness is down to a specific problem (Reckitt’s decision to buy Mead Johnson in 2017 stands out).
In other words, it’s clear that firms are struggling to balance pricing power against volumes. Many have put up prices to pass on higher costs and protect margins. This kept both revenues and profits growing, but caused the volume of goods sold to shrink. You can’t keep doing that forever, because higher prices and shrinking sizes may cause shoppers to trade down to cheaper brands permanently.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
However, there is another trend in play. We’ve also seen notable weakness in both results and share prices for spirits firms, breweries (Heineken), beauty (L’Oréal), luxury goods (LVMH) and more. What links many of these together is not just uncertainty about consumer demand right now, but how much long-term value we should put on the power of a brand.
Are consumer stocks still popular?
Top consumer brands produce higher and more reliable earnings, and so investors have been willing to pay higher valuations for these stocks. A compelling growth story – typically in emerging markets, where consumers buy more branded goods from snacks to toothpaste to cosmetics to luxuries as they become wealthier – also helped justify premium multiples.
Now it looks as if investors are getting a bit more wary about this. After expanding for many years – since the global financial crisis in some cases – multiples are now contracting. At the end of 2019, Diageo traded on about 23 times forecast earnings. Now it trades on under 15. The shrinking multiple has made a much bigger difference to the share price than the change in earnings.
This isn’t happening in all stocks, and it is far more pronounced in Europe than the US, but there is a trend towards less bullish valuations. The question is whether that reflects investors getting unduly rattled over short-term earnings or rethinking some structural issues. Perhaps margins may have to come down for years, not quarters, to defend market share.
Maybe social shifts will cause younger generations to drink fewer spirits. New anti-obesity drugs could curb demand for snack food, alcohol and other impulses. Weaker long-term growth in emerging markets would mean fewer new consumers. On the financial side of the equation, higher interest rates reduce the attraction of the steady dividends that many of these stocks pay.
Reratings do not just go one way. Unilever, which was firmly out of favour, is being rewarded with a higher multiple as markets come to trust in a turnaround. However, it seems likely that consumer stocks in general will get less of a valuation tailwind for a while.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Cris Sholto Heaton is an investment analyst and writer who has been contributing to MoneyWeek since 2006 and was managing editor of the magazine between 2016 and 2018. He is especially interested in international investing, believing many investors still focus too much on their home markets and that it pays to take advantage of all the opportunities the world offers. He often writes about Asian equities, international income and global asset allocation.
Cris began his career in financial services consultancy at PwC and Lane Clark & Peacock, before an abrupt change of direction into oil, gas and energy at Petroleum Economist and Platts and subsequently into investment research and writing. In addition to his articles for MoneyWeek, he also works with a number of asset managers, consultancies and financial information providers.
He holds the Chartered Financial Analyst designation and the Investment Management Certificate, as well as degrees in finance and mathematics. He has also studied acting, film-making and photography, and strongly suspects that an awareness of what makes a compelling story is just as important for understanding markets as any amount of qualifications.
-
How Corpay is cashing in on expenses
Financial technology company Corpay has found a profitable niche managing corporate payments
By Dr Matthew Partridge Published
-
Are UK Reits the most unloved asset?
Recent updates from UK Reits are looking more positive, but the market remains entirely unimpressed
By Cris Sholto Heaton Published
-
Why CEOs deserve a pay rise
Opinion The CEOs of big companies often come under fire for being grossly overpaid. But the truth, as per some economists, is the opposite. Do they merit a pay rise?
By Stuart Watkins Published
-
Rolls-Royce stock jumps 15% – could it climb further?
Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
By Dr Matthew Partridge Published
-
The power of private markets
Interview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
By Andrew Van Sickle Published
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success
By Dr Mike Tubbs Published
-
Global investors have overlooked these top tips in emerging markets
Opinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
By Chris Tennant Published
-
King Coal has not been dethroned yet — should you buy?
The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
By Rupert Hargreaves Published
-
It’s time to start buying Europe again, says Merryn Somerset Webb
Opinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
By Merryn Somerset Webb Published
-
Prosus to buy Just Eat for €4.1 billion as takeaway boom fades
Food-delivery platform Just Eat has been gobbled up by a Dutch rival. Now there could be further consolidation in the sector
By Dr Matthew Partridge Published